Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

GLP-1 receptor agonists

Generic Name: GLP-1 receptor agonists

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Research of Intensive Lifestyle Intervention for PCOS Patients With IGT

Not Applicable

Completed

Posted: 2015/05/18

Sponsor:RenJi Hospital

ID:NCT02446834

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Actimed Therapeutics Launches Program to Combat Muscle Loss in GLP-1 Treated Obesity Patients

8 days ago

Actimed Therapeutics has initiated a two-part development program investigating S-pindolol benzoate for preserving muscle mass in patients on GLP-1 receptor agonist therapy for obesity.

Weight-Loss Injections Show Promise for Obese Children, Reducing Mealtime Conflicts

15 days ago

GLP-1 receptor agonists helped obese children lose 5-16% of body weight after one year of treatment when combined with lifestyle interventions, according to research presented at the European Congress on Obesity.

Saudi Arabia Seeks to Localize Insulin and GLP-1 Production Through Novo Nordisk Partnership

17 days ago

Saudi Industry Minister Bandar Al-Khorayef is visiting Denmark to strengthen pharmaceutical partnerships, with a focus on bringing insulin and GLP-1 production to Saudi Arabia through collaboration with Novo Nordisk.

WHO Set to Endorse GLP-1 Weight Loss Drugs Globally, Addressing Access Challenges

a month ago

The World Health Organization plans to officially recommend GLP-1 receptor agonists like Wegovy and Zepbound for adult obesity treatment globally, with guidelines expected by September 2024.